FindTrial
Sign In

Phase II trial of apatinib in the treatment of metastatic penile cancer

Phase II trial of apatinib in the treatment of metastatic penile cancer - Phase II trial of apatinib in the treatment of metastatic penile cancer

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000021849
Enrollment
26
Registered
2016-04-10
Start date
2016-04-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

phase II ,single arm

Interventions

apatinib 500mg qd

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed penile squamous cell carcinoma 2) M1 disease 3) At least one measurable tumor lesion 4) ECOG PS 0-1 5) Age 18-75 6) Normal organ function 7) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Usage of experimental drugs 2) History of serious drug allergy 3) uncontrolled hemorrhage 4) PS>1 5) heart failure 6) Double cancer 7) Coexisting severe medical conditions 8) Mental disease 9) Judged as inappropriate to participate this trial by investigators

Design outcomes

Primary

MeasureTime frame
Progression free survival,—

Secondary

MeasureTime frame
objective response rate; overall survival—

Countries

Asia(except Japan)

Contacts

Public ContactSheng Zhang

Fudan University Shanghai Cancer Center medical oncology

wozhangsheng@hotmail.com21-64175590

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 8, 2026